The First Experience of Effective 3rd Line Antiretroviral Therapy – A Case of 40-Year-Old Female Retroviral-Infected Patient at Hawassa University Comprehensive Specialized Hospital, Hawassa, Sidama, Ethiopia
| Autor: | Worku Ketema, Agete Tadewos Hirigo, Alemayehu Toma, Mulugeta Sitot Shibeshi, Negash Tagesse, Selamawit Gutema, Aberash Eifa, Kefyalew Taye, Kindie Woubishet |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Pediatrics
medicine.medical_specialty business.industry Art therapy undetectable viral load third line ART General Engineering Lamivudine Case Report darunavir medicine.disease Antiretroviral therapy chemistry.chemical_compound chemistry Acquired immunodeficiency syndrome (AIDS) Dolutegravir medicine General Earth and Planetary Sciences Ritonavir business Viral load Darunavir General Environmental Science medicine.drug |
| Zdroj: | Research and Reports in Tropical Medicine |
| ISSN: | 1179-7282 |
| Popis: | Background Treatment failure continues to be an impediment to the efficacy of highly active antiretroviral therapy (HART) in the treatment of human immunodeficiency virus type 1 infection (HIV-1). The World Health Organization (WHO) recommends third-line antiretroviral therapy (ART) for patients who have failed second-line ART. Darunavir (DRV) boosted with ritonavir (DRV/r) has a higher genetic barrier to resistance, is active against multidrug-resistant HIV isolates, retaining virological activity even when multiple protease mutations are present, and has been shown to be cost-effective when compared to other boosted protease inhibitors (PIs). Case Summary This is a case of a 40-year-old female known HIV/AIDS patient who has been on ART for the last 14 years with good adherence and regular follow-up, and who is now on 3rd line ART medication with TLD (tenofovir/lamivudine/dolutegravir)+DRV/r (in her 11th month) after being diagnosed with second-line treatment failure. After 6 months and 1 week of therapy, the viral load (VL) was sent, and the result was undetectable. The patient's clinical conditions had greatly improved. Conclusion Third-line ART therapy, which was once thought to be a salvageable treatment, is now the primary option for second-line ART failure. TLD in combination with ritonavir-boosted darunavir is found to be effective at lowering viral loads in the blood below detectable limits. Despite a lack of data on the use of third-line ART in Ethiopia, access to third-line ART containing ritonavir-boosted darunavir is recommended because it has been shown to be an effective alternative for patients who have failed second-line ART. We recommend that more research be done with a larger sample size, and that the findings in this paper be used with caution. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|